ClinicalTrials.gov
public full text
Public Domain
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT
This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS#805356
- Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS#861681
- Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT#832011
- Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT#829306
- Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML#1114177
Record · ID 993451
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive